Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
120M
-
Number of holders
-
132
-
Total 13F shares, excl. options
-
67.1M
-
Shares change
-
-3.49M
-
Total reported value, excl. options
-
$356M
-
Value change
-
-$30M
-
Put/Call ratio
-
5.86
-
Number of buys
-
70
-
Number of sells
-
-55
-
Price
-
$5.31
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q3 2023
164 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock as of Q3 2023.
Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) has 132 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67.1M shares
of 120M outstanding shares and own 55.83% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (8.68M shares), FMR LLC (8.26M shares), Rubric Capital Management LP (5.03M shares), JENNISON ASSOCIATES LLC (4.43M shares), STATE STREET CORP (4.36M shares), BlackRock Inc. (4.02M shares), Polar Capital Holdings Plc (3.12M shares), Bain Capital Life Sciences Investors, LLC (3M shares), VANGUARD GROUP INC (2.88M shares), and MARSHALL WACE, LLP (2.31M shares).
This table shows the top 132 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.